Ajinomoto Althea, a provider of biotherapeutic contract development and manufacturing services, has been issued U.S. Patent 9,310,379 covering methods to crystallize monoclonal antibodies for the purpose of scale up and cGMP manufacturing for therapeutic use. The company says the patented methods are important for successful stabilization, storage and delivery of biologically active antibody crystals. “This patent further validates Althea’s unique expertise and proprietary capabilities in the...